The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | Advancements in EGFR-targeted therapies for lung cancer
Anna Minchom, MD, BCh, MB, MRCP, The Royal Marsden Hospital, London, UK, discusses novel advancements in the treatment of lung cancer. She highlights the rapid progress in EGFR-targeted therapies, including osimertinib-chemotherapy and amivantamab combinations, as well as patient selection for these evolving treatments in EGFR lung cancer. This interview took place at the BTOG 2025 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
